Objective: To investigate whether metabolic syndrome (MetS) may be associated with the clinical progression of benign prostatic hyperplasia (BPH). Methods: A total of 525 community-dwelling men (aged 45-78) with lower urinary tract symptoms (LUTS) who had complete data at 3-year follow-up were included in this prospective study. International Prostate Symptom Score (IPSS) questionnaire, prostate ultrasonography for prostate volume (PV), maximum urine flow rate (Qmax) and biological parameters were recorded. Participants were divided into a BPH with the MetS group and a BPH without the MetS group, and all received a 3-year follow-up to monitor possible correlations between LUTS/BPH clinical progression and MetS. Results: The results showed that MetS was associated with IPSS, Qmax and PV (p < 0.05) after 3-year follow-up. The mean change of IPSS, PV and Qmax were positively and negatively correlated with time in the BPH with MetS group during the 3-year follow-up. In addition, the BPH clinical progression rate was significantly higher in the BPH with MetS group, compared with the BPH without MetS group (p < 0.05). Diabetes mellitus (DM) and hypertension were related to increased risk of BPH clinical progression. Conclusions: The present results suggest that MetS, in particular, DM and hypertension, may accelerate the clinical progression of BPH in community-dwelling middle-aged and older men.

Keywords:
Benign prostatic hyperplasia, Clinical progression, Lower urinary tract symptoms, Metabolic syndrome
1.
Platz EA, Smit E, Curhan GC, Nyberg LM, Giovannucci E: Prevalence of and racial/ethnic variation in lower urinary tract symptoms and noncancer prostate surgery in U.S. men. Urology 2002;59:877-883.
2.
McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg LM Jr, Clarke HS, Crawford ED, Diokno A, Foley JP, Foster HE, Jacobs SC, Kaplan SA, Kreder KJ, Lieber MM, Lucia MS, Miller GJ, Menon M, Milam DF, Ramsdell JW, Schenkman NS, Slawin KM, Smith JA; Medical Therapy of Prostatic Symptoms (MTOPS) Research Group: The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349:2387-2398.
3.
Gu D, Reynolds K, Wu X, Chen J, Duan X, Reynolds RF, Whelton PK, He J; InterASIA Collaborative Group: Prevalence of the metabolic syndrome and overweight among adults in China. Lancet 2005;365:1398-1405.
4.
Lim S, Shin H, Song JH, Kwak SH, Kang SM, Won Yoon J, Choi SH, Cho SI, Park KS, Lee HK, Jang HC, Koh KK: Increasing prevalence of metabolic syndrome in Korea: the Korean national health and nutrition examination survey for 1998-2007. Diabetes Care 2011;34:1323-1328.
5.
Hammarsten J, Peeker R: Urological aspects of the metabolic syndrome. Nat Rev Urol 2011;8:483-494.
6.
Ozden C, Ozdal OL, Urgancioglu G, Koyuncu H, Gokkaya S, Memis A: The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur Urol 2007;51:199-206; discussion 204-206.
7.
Zou C, Gong D, Fang N, Fan Y: Meta-analysis of metabolic syndrome and benign prostatic hyperplasia in Chinese patients. World J Urol 2016;34:281-289.
8.
Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F: Diagnosis and management of the metabolic syndrome: an American heart association/national heart, lung, and blood institute scientific statement. Circulation 2005;112:2735-2752.
9.
Gacci M, Corona G, Vignozzi L, Salvi M, Serni S, De Nunzio C, Tubaro A, Oelke M, Carini M, Maggi M: Metabolic syndrome and benign prostatic enlargement: a systematic review and meta-analysis. BJU Int 2015;115:24-31.
10.
Yeh HC, Liu CC, Lee YC, Wu WJ, Li WM, Li CC, Hour TC, Huang CN, Chang CF, Huang SP: Associations of the lower urinary tract symptoms with the lifestyle, prostate volume, and metabolic syndrome in the elderly males. Aging Male 2012;15:166-172.
11.
Kupelian V, McVary KT, Kaplan SA, Hall SA, Link CL, Aiyer LP, Mollon P, Tamimi N, Rosen RC, McKinlay JB: Association of lower urinary tract symptoms and the metabolic syndrome: results from the Boston area community health survey. J Urol 2013;189(1 suppl):S107-S114; discussion S115-S116.
12.
Pashootan P, Ploussard G, Cocaul A, de Gouvello A, Desgrandchamps F: Association between metabolic syndrome and severity of lower urinary tract symptoms (LUTS): an observational study in a 4666 European men cohort. BJU Int 2015;116:124-130.
13.
Yin Z, Yang JR, Rao JM, Song W, Zhou KQ: Association between benign prostatic hyperplasia, body mass index, and metabolic syndrome in Chinese men. Asian J Androl 2015;17:826-830.
14.
Park YW, Kim SB, Kwon H, Kang HC, Cho K, Lee KI, Kim YJ, Lee JH: The relationship between lower urinary tract symptoms/benign prostatic hyperplasia and the number of components of metabolic syndrome. Urology 2013;82:674-679.
15.
Burke JP, Jacobson DJ, Mcgree ME, Roberts RO, Girman CJ, Lieber MM, Jacobsen SJ: Diabetes and benign prostatic hyperplasia progression in Olmsted county, Minnesota. Urology 2006;67:22-25.
16.
De Nunzio C, Aronson W, Freedland SJ, Giovannucci E, Parsons JK: The correlation between metabolic syndrome and prostatic diseases. Eur Urol 2012;61:560-570.
17.
Pan JG, Liu M, Zhou X: Relationship between lower urinary tract symptoms and metabolic syndrome in a Chinese male population. J Endocrinol Invest 2014;37:339-344.
18.
Zhang X, Zeng X, Liu Y, Dong L, Zhao X, Qu X: Impact of metabolic syndrome on benign prostatic hyperplasia in elderly Chinese men. Urol Int 2014;93:214-219.
19.
Kwon H, Kang HC, Lee JH: Relationship between predictors of the risk of clinical progression of benign prostatic hyperplasia and metabolic syndrome in men with moderate to severe lower urinary tract symptoms. Urology 2013;81:1325-1329.
20.
Gacci M, Vignozzi L, Sebastianelli A, Salvi M, Giannessi C, De Nunzio C, Tubaro A, Corona G, Rastrelli G, Santi R, Nesi G, Serni S, Carini M, Maggi M: Metabolic syndrome and lower urinary tract symptoms: the role of inflammation. Prostate Cancer Prostatic Dis 2013;16:101-106.
21.
Rohrmann S, Smit E, Giovannucci E, Platz EA: Association between markers of the metabolic syndrome and lower urinary tract symptoms in the third national health and nutrition examination survey (NHANES III). Int J Obes (Lond) 2005;29:310-316.
22.
Park HK, Lee HW, Lee KS, Byun SS, Jeong SJ, Hong SK, Lee SE, Park JH, Lee SB, Kim KW; Korean Longitudinal Study on Health and Aging: Relationship between lower urinary tract symptoms and metabolic syndrome in a community-based elderly population. Urology 2008;72:556-560.
23.
Hammarsten J, Högstedt B, Holthuis N, Mellström D: Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 1998;1:157-162.
24.
Burke JP, Rhodes T, Jacobson DJ, McGree ME, Roberts RO, Girman CJ, Lieber MM, Jacobsen SJ: Association of anthropometric measures with the presence and progression of benign prostatic hyperplasia. Am J Epidemiol 2006;164:41-46.
25.
Telli O, Demirbas A, Kabar M, Karagoz MA, Sarici H, Resorlu B: Does metabolic syndrome or its components correlate with lower urinary tract symptoms in benign prostatic hyperplasia patients? NephroUrol Mon 2015;7:e27253.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.